Common crossroads in diabetes management

Osteopathic Medicine and Primary Care

Volumn 2, Issue , 2008, Pages

  Valitutto, Michael ^a  

^a BORGESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 41549138300     PISSN: None     EISSN: 17504732     Source Type: Journal    
DOI: 10.1186/1750-4732-2-4     Document Type: Review

References (73)

1. Rosamond W Flegal K Friday G Furie K Go A Greenlund K Haase N Ho M Howard V Kissela B Kittner S Lloyd-Jones D McDermott M Meigs J Moy C Nichol G O'Donnell CJ Roger V Rumsfeld J Sorlie P Steinberger J Thom T Wasserthiel-Smoller S Hong Y Heart disease and stroke statistics - 2007 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 2007, 115:e69-e171 10.1161/CIRCULATIONAHA.106.179918 17194875
2. Centers for Disease Control and Prevention National diabetes fact sheet: United States, 2005: General information 2005 http://www.cdc.gov/ diabetes/pubs/pdf/ndfs_2005.pdf
3. Samuel-Hodge CD Headen SW Skelly AH Ingram AF Keyserling TC Jackson EJ Ammerman AS Elasy TA Influences on day-to-day self-management of type 2 diabetes among African-American women: Spirituality, the multi-caregiver role, and other social context factors Diabetes Care 2000, 23:928-933 10.2337/diacare.23.7.928 10895842
4. Utz SW Steeves RH Wenzel J Hinton I Jones RA Andrews D Muphy A Oliver MN "Working hard with it": Self-management of type 2 diabetes by rural African Americans Fam Community Health 2006, 29:195-205 16775469
5. Leslie CA Satin-Rapaport W Matheson D Stone R Enfield G Psychological insulin resistance: A missed diagnosis? Diabetes Spectrum 1994, 7:52-57
6. DeWitt DE Hirsch IB Outpatient insulin therapy in type 1 and type 2 diabetes mellitus: Scientific review JAMA 2003, 289:2254-2264 10.1001/ jama.289.17.2265 12734137
7. DeFronzo RA Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetes genes Diabetes Rev 1997, 5:177-269
8. UK Prospective Diabetes Study Group U.K. Prospective Diabetes Study 16. Overview of 6 years' therapy of type II diabetes: A progressive disease Diabetes 1995, 44:1249-1258 10.2337/diabetes.44.11.1249 7589820
9. American Diabetes Association Standards of medical care in diabetes - 2007 Diabetes Care 2007, 30(Suppl 1):S4-S41 10.2337/dc07-S004 17192377
10. American Association of Clinical Endocrinologists The American Association of Clinical Endocrinologists medical guidelines for the management of diabetes mellitus: The AACE system of intensive diabetes self-management-2002 update Endocr Pract 2002, 8(Suppl 1):40-82
11. Monnier L Lapinski H Colette C Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: Variations with increasing levels of HbA1c Diabetes Care 2003, 26:881-885 10.2337/diacare.26.3.881 12610053
12. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998, 352:837-853 10.1016/S0140-6736(05)61359-1 9742976
13. Dormandy JA Charbonnel B Eckland DJA Erdmann E Massi-Benedetti M Moules IK Skene AM Tan MH Lefèbvre PJ Murray GD Standl E Wilcox RG Wilhelmsen L Betteridge J Birkeland K Golay A Heine RJ Korányi L Laakso M Mokáò M Norkus A Pirags V Podar T Scheen A Scherbaum W Schernthaner G Schmitz O Škrha J Smith U Tatoň J on behalf of the PROactive investigators Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial Lancet 2005, 366:1279-1289 10.1016/ S0140-6736(05)67528-9 16214598
14. The Diabetes Control and Complication Trial (DCCT) Research Group Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial Am J Cardiol 1995, 75:894-903 10.1016/S0002-9149(99)80683-3 7732997
15. The Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complication (DCCT/EDIC) Study Research Group Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes N Engl J Med 2005, 353:2643-2653 10.1056/NEJMoa052187 16371630
16. Resnick HE Foster GL Bardsley J Ratner RE Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999-2002: The National Health and Nutrition Examination Survey Diabetes Care 2006, 29:531-537 10.2337/diacare.29.03.06.dc05-1254 16505501
17. Gerstein HC Pogue J Mann JFE Lonn E Dagenais GR McQueen M Yusuf S HOPE Investigators The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: A prospective epidemiological analysis Diabetologia 2005, 48:1749-1755 10.1007/s00125-005-1858-4 16059716
18. ACE/AACE Diabetes Road Map Task Force Road maps to achieve glycemic control in type 2 diabetes mellitus Endocr Pract 2007, 13:260-268 http://www.aace.com/meetings/consensus/odimplimentation/roadmap.pdf 17599857
19. Nathan DM Buse JB Davidson MB Heine RJ Holman RR Sherwin R Zinman B Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the EUropean Association for the Study of Diabetes Diabetes Care 2006, 29:1963-1972 10.2337/dc06-9912 16873813
20. Dailey G A timely transition to insulin: Identifying type 2 diabetes patients failing oral therapy Formulary 2005, 40:114-130
21. Davies M Storms F Shutler S Bianchi-Biscay M Gomis R Lantus Study Group AT.LANTUS trial investigating treatment algorithms for insulin glargine (LANTUS): Results of the type 2 study [abstract 1980-PO] Diabetes 2004, 53(Suppl 2):A473
22. Davies M Storms F Shutler S Bianchi-Biscay M Gomis R for the AT.LANTUS STudy Group Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: Comparison of two treatment algorithms using insulin glargine Diabetes Care 2005, 28:1282-1288 10.2337/ diacare.28.6.1282 15920040
23. Riddle MC Rosenstock J Gerich J on behalf of the Insulin Glargine 4002 Study Investigators The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients Diabetes Care 2003, 26:3080-3086 10.2337/diacare.26.11.3080 14578243
24. Ziemer DC Miller CD Rhee MK Doyle JP Watkins C Jr Cook CB Gallina DL El-Kebbi IM Barnes CS Dunbar VG Branch WT Jr Phillips LS Clinical inertia contributes to poor diabetes control in a primary care setting Diabetes Educ 2005, 31:564-571 10.1177/0145721705279050 16100332
25. Cook CB Ziemer DC El-Kebbi IM Gallina DL Dunbar VG Ernst KL Phillips LS Diabetes in urban African-Americans. XVI. Overcoming clinical inertia improves glycemic control in patients with type 2 diabetes Diabetes Care 1999, 22:1494-1500 10.2337/diacare.22.9.1494 10480515
26. Gerstein HC Yale J-F Harris SB Issa M Stewart JA Dempsey E A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study Diabet Med 2006, 23:736-742 10.1111/ j.1464-5491.2006.01881.x 16842477
27. Dandona P Mohanty P Chaudhuri A Garg R Aljada A Insulin infusion in acute illness J Clin Invest 2005, 115:2069-2072 1180564 16075050 10.1172/ JCI26045
28. Nissen SE Wolski K Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 2007, 356:2457-2471 10.1056/NEJMoa072761 17517853
29. Home PD Pocock SJ Beck-Nielsen H Gomis R Hanefeld M Jones NP Komajda M McMurray JJV for the RECORD Study Group Rosiglitazone evaluated for cardiovascular outcomes - an interim analysis N Engl J Med 2007, 357:28-38 10.1056/NEJMoa073394 17551159
30. Langouche L Vanhorebeek I Vlasselaers D Vander Perre S Wouters PJ Skogstrand K Hansen TK Van den Berghe G Intensive insulin therapy protects the endothelium of critically ill patients J Clin Invest 2005, 115:2277-2286 1180545 16075063 10.1172/JCI25385
31. Wright A Burden ACF Paisey RB Cull CA Holman RR for the UK Prospective Diabetes Study Group Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57) Diabetes Care 2002, 25:330-336 10.2337/diacare.25.2.330 11815505
32. Rosenstock J Insulin therapy: Optimizing control in type 1 and type 2 diabetes Clin Cornerstone 2001, 4:50-64 10.1016/S1098-3597(01)90029-8 11838327
33. Mooradian AD Bernbaum M Albert SG Narrative review: A rational approach to starting insulin therapy Ann Intern Med 2006, 145:125-134 16847295
34. HOE 901/2004 Study Investigators Group Safety and efficacy of insulin glargine (HOE 901) versus NPH insulin in combination with oral treatment in Type 2 diabetic patients Diabet Med 2003, 20:545-551 10.1046/ j.1464-5491.2003.00999.x 12823235
35. Yki-Järvinen H Dressler A Ziemen M Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes Diabetes Care 2000, 23:1130-1136 10.2337/ diacare.23.8.1130 10937510
36. Yki-Jarvinen H Häring H-U Johnson E Arbet-Engels C Nguyen HH Zege S Riddle M The relationship between glycemic control and hypoglycemia using insulin glargine versus NPH insulin: A meta-regression analysis in type 2 diabetes Abstract presented at: 63rd Annual Scientific Session of the American Diabtes Association; June 13-17, 2003 New Orleans, LA Abstract 642-P
37. Levemir [package insert] Princeton, NJ: Novo Nordisk Inc 2005 http://www.levemir-us.com/prescribing_information.pdf
38. Hermansen K Davies M Derezinski T Martinez Ravn G Clauson P Home P on behalf of the Levemir Treat-to-Target Study Group A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes Diabetes Care 2006, 29:1269-1274 10.2337/dc05-1365 16732007
39. Schwartz S Sievers R Strange P Lyness WH Hollander P for the INS-2061 Study Team Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysis Diabetes Care 2003, 26:2238-2243 10.2337/diacare.26.8.2238 12882842
40. Wittlin SD Woehrle HJ Gerich JE Insulin pharmacokinetics Insulin Therapy New York, NY: Marcel Dekker, Inc Leahy JL, Cefalu WT 2002, 73-85
41. Rave K Klein O Frick AD Becker RHA Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes Diabetes Care 2006, 29:1812-1817 10.2337/dc06-0383 16873785
42. Humalog [package insert] Indianapolis, IN: Eli Lilly and Company 2007 http://pi.lilly.com/us/humalog-pi.pdf
43. Ross SA Zinman B Campos RV Strack T Canadian Lispro Study Group A comparative study of insulin lispro and human regular insulin in patients with type 2 diabetes mellitus and secondary failure of oral hypoglycemic agents Clin Invest Med 2001, 24:292-298 11767232
44. NovoLog [physician insert] Princeton, NJ: Novo Nordisk Inc 2007 http://www.novolog.com/NovoLog_Precribing_Info.pdf
45. Rašlová K Bogoev M Raz I Leth G Gall M-A Hâncu N Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes Diabetes Res Clin Pract 2004, 66:193-201 10.1016/ j.diabres.2004.03.003 15533587
46. Jungmann E Preprandial vs. postprandial injections of insulin glulisine in intensified insulin therapy of obese patients with type 2 diabetes mellitus Abstract presented at: 66th Annual Scientific Sessions of the American Diabetes Association; June 5-9, 2006 Washington, DC Abstract 495-P
47. Bergenstal R Johnson ML Powers MA Wynne AG Vlajnic A Hollander PA Using a simple algorithm (ALG) to adjust mealtime glulisine (GLU) based on pre-prandial glucose patterns is a safe and effective alternative to carbohydrate counting (Carb Count) Abstract presented at: 66th Annual Scientific Sessions of the American Diabetes Association; June 5-9, 2006 Washington, DC Abstract 441-P
48. Apidra [package insert] Kansas City, MO: Aventis Pharmaceuticals Inc 2007 http://products.sanofi-aventis.us/apidra/ apidra.html#Dosage%20and%20Administration]
49. Oiknine R Bernbaum M Mooradian AD A critical appraisal of the role of insulin analogues in the management of diabetes mellitus Drugs 2005, 65:325-340 10.2165/00003495-200565030-00003 15669878
50. Exubera [prescribing information] New York, NY: Pfizer Inc 2007 http://www.pfizer.com/pfizer/download/uspi_exubera.pdf
51. Riddle MC Drucker DJ Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1 Diabetes Care 2006, 29:435-449 10.2337/ diacare.29.02.06.dc05-1267 16443905
52. Food and Drug Administration FDA approves first ever inhaled insulin combination product for treatment of diabetes 2006 http://www.fda.gov/ bbs/topics/news/2006/NEW01304.html
53. Dunn C Curran MP Inhaled human insulin (Exubera): A review of its use in adult patients with diabetes mellitus Drugs 2006, 66:1013-1032 10.2165/ 00003495-200666070-00019 16740022
54. Lam S See S Exenatide: A novel incretin mimetic agent for treating type 2 diabetes mellitus Cardiol Rev 2006, 14:205-211 10.1097/ 01.crd.0000223655.16253.e4 16788334
55. Buse JB Henry RR Han J Kim DD Fineman MS Baron AD for the Exenatide-113 Clinical Study Group Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes Diabetes Care 2004, 27:2628-2635 10.2337/diacare.27.11.2628 15504997
56. DeFronzo RA Ratner RE Han J Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care 2005, 28:1092-1100 10.2337/diacare.28.5.1092 15855572
57. Kendall DM Riddle MC Rosenstock J Zhuang D Kim DD Fineman MS Baron AD Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea Diabetes Care 2005, 28:1083-1091 10.2337/diacare.28.5.1083 15855571
58. Heine RJ Van Gaal LF Johns D Mihm MJ Widel MH Brodows RG for the GWAA STudy Group Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial Ann Intern Med 2005, 143:559-569 16230722
59. Mikhail NE Is exenatide a useful addition to diabetes therapy? Endocr Pract 2006, 12:307-314 16772206
60. U.S.Food and Drug Administration Exenatide (marketed as Byetta) information 2007
61. Byetta [prescribing information] San Diego, CA: Amylin Pharmaceuticals, Inc 2007 http://pi.lilly.com/us/byetta-pi.pdf
62. Lebovitz HE Therapeutic options in development for management of diabetes: Pharmacologic agents and new technologies Endocr Pract 2006, 12(Suppl 1):142-147 16627399
63. Charbonnel B Karasik A Liu J Wu M Meininger G for the Sitagliptin Study 020 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2006, 29:2638-2643 10.2337/dc06-0706 17130197
64. Januvia [prescribing information] Whitehouse Station, NJ: Merck & Co., Inc 2007 http://www.merck.com/product/usa/pi_circulars/j/ januvia_pi.pdf
65. Rosenstock J Brazg R Andryuk PJ McCrary Sisk C Lu K Stein P Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM) Abstract presented at: 66th Annual Scientific Sessions of the American Diabetes Association; June 5-9, 2006 Washington, DC Abstract 556-P
66. Nonaka K Kakikawa T Sato A Okuyama K Fujimoto G Hayashi N Suzuki H Hirayama Y Stein P Twelve-week efficacy and tolerability of Sitagliptin, a dipeptidyl peptidase-IV (DPP-4) inhibitor, in Japanese patients with T2DM Abstract presented at: 66th Annual Scientific Sessions of the American Diabetes Association; June 5-9, 2006 Washington, DC Abstract 537-P
67. Peck P FDA okays sitagliptin (Januvia)-metformin combo tablet 2007 http://www.medpagetoday.com/ProductAlert/Prescription/tb/5378
68. Good Publication Practice for pharmaceutical companies http://www.gpp-guidelines.org
69. Lepore M Pampanelli S Fanelli C Porcellati F Bartocci L Di Vincenzo A Cordoni C Costa E Brunetti P Bolli GB Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro Diabetes 2000, 49:2142-2148 10.2337/diabetes.49.12.2142 11118018
70. Rosenstock J Dailey G Massi-Benedetti M Fritsche A Lin Z Salzman A Reduced hypoglycemia risk with insulin glargine: A meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes Diabetes Care 2005, 28:950-955 10.2337/diacare.28.4.950 15793205
71. Danne T Lüpke K Walte K von Schuetz W Gall MA Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes Diabetes Care 2003, 26:3087-3092 10.2337/diacare.26.11.3087 14578244
72. Becker RHA Frick AD Burger F Potgieter JH Scholtz H Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects Exp Clin Endocrinol Diabetes 2005, 113:435-443 10.1055/s-2005-865806 16151977
73. Garg S Chen Y Souhami E Reduction in insulin dose and body weight with pre- and post-meal insulin glulisine (GLU) versus regular human insulin (RHI) in patients with type 1 diabetes Abstract presented at: 65th Annual Scientific Sessions of the American Diabetes Association; June 10-14, 2005 San Diego, CA Abstract 581-P